vs

Side-by-side financial comparison of Indivior Pharmaceuticals, Inc. (INDV) and KENNAMETAL INC (KMT). Click either name above to swap in a different company.

KENNAMETAL INC is the larger business by last-quarter revenue ($592.6M vs $357.0M, roughly 1.7× Indivior Pharmaceuticals, Inc.). Indivior Pharmaceuticals, Inc. runs the higher net margin — 28.9% vs 10.3%, a 18.5% gap on every dollar of revenue.

Indivior is a global specialty pharmaceutical company dedicated to developing and commercializing evidence-based treatments for substance use disorders such as opioid use disorder and alcohol dependence, as well as related mental health conditions. Its primary operating markets are North America and Europe, with a portfolio of approved therapies targeting unmet medical needs for underserved patient groups.

Kennametal, Inc. is a manufacturer of high-performance cutting tools and engineered components used in the aerospace, defense, transportation and oil and gas drilling industries. Its customer base is global.

INDV vs KMT — Head-to-Head

Bigger by revenue
KMT
KMT
1.7× larger
KMT
$592.6M
$357.0M
INDV
Higher net margin
INDV
INDV
18.5% more per $
INDV
28.9%
10.3%
KMT

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
INDV
INDV
KMT
KMT
Revenue
$357.0M
$592.6M
Net Profit
$103.0M
$61.1M
Gross Margin
82.1%
35.1%
Operating Margin
22.7%
13.4%
Net Margin
28.9%
10.3%
Revenue YoY
21.8%
Net Profit YoY
390.5%
85.0%
EPS (diluted)
$0.79
$0.75

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INDV
INDV
KMT
KMT
Q1 26
$592.6M
Q4 25
$357.0M
$529.5M
Q3 25
$314.0M
$498.0M
Q2 25
$302.0M
$516.4M
Q1 25
$266.0M
$486.4M
Q4 24
$482.1M
Q3 24
$307.0M
$481.9M
Q2 24
$299.0M
$543.3M
Net Profit
INDV
INDV
KMT
KMT
Q1 26
$61.1M
Q4 25
$103.0M
$33.9M
Q3 25
$42.0M
$23.3M
Q2 25
$18.0M
$21.6M
Q1 25
$47.0M
$31.5M
Q4 24
$17.9M
Q3 24
$22.0M
$22.1M
Q2 24
$-97.0M
$37.2M
Gross Margin
INDV
INDV
KMT
KMT
Q1 26
35.1%
Q4 25
82.1%
32.8%
Q3 25
73.2%
31.0%
Q2 25
82.8%
28.2%
Q1 25
83.1%
32.1%
Q4 24
30.1%
Q3 24
78.5%
31.3%
Q2 24
73.6%
31.5%
Operating Margin
INDV
INDV
KMT
KMT
Q1 26
13.4%
Q4 25
22.7%
9.9%
Q3 25
13.7%
7.5%
Q2 25
23.8%
6.1%
Q1 25
24.8%
9.1%
Q4 24
6.6%
Q3 24
11.4%
7.5%
Q2 24
-39.5%
11.3%
Net Margin
INDV
INDV
KMT
KMT
Q1 26
10.3%
Q4 25
28.9%
6.4%
Q3 25
13.4%
4.7%
Q2 25
6.0%
4.2%
Q1 25
17.7%
6.5%
Q4 24
3.7%
Q3 24
7.2%
4.6%
Q2 24
-32.4%
6.8%
EPS (diluted)
INDV
INDV
KMT
KMT
Q1 26
$0.75
Q4 25
$0.79
$0.44
Q3 25
$0.33
$0.30
Q2 25
$0.14
$0.28
Q1 25
$0.38
$0.41
Q4 24
$0.23
Q3 24
$0.16
$0.28
Q2 24
$-0.72
$0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INDV
INDV
KMT
KMT
Cash + ST InvestmentsLiquidity on hand
$195.0M
$106.8M
Total DebtLower is stronger
$597.4M
Stockholders' EquityBook value
$-98.0M
Total Assets
$1.2B
$2.7B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INDV
INDV
KMT
KMT
Q1 26
$106.8M
Q4 25
$195.0M
$129.3M
Q3 25
$445.0M
$103.5M
Q2 25
$510.0M
$140.5M
Q1 25
$373.0M
$97.5M
Q4 24
$121.2M
Q3 24
$119.6M
Q2 24
$128.0M
Total Debt
INDV
INDV
KMT
KMT
Q1 26
$597.4M
Q4 25
$597.2M
Q3 25
$597.0M
Q2 25
$596.8M
Q1 25
$596.6M
Q4 24
$596.4M
Q3 24
$596.2M
Q2 24
$596.0M
Stockholders' Equity
INDV
INDV
KMT
KMT
Q1 26
Q4 25
$-98.0M
$1.3B
Q3 25
$-207.0M
$1.3B
Q2 25
$-257.0M
$1.3B
Q1 25
$-285.0M
$1.2B
Q4 24
$1.2B
Q3 24
$-310.0M
$1.3B
Q2 24
$-281.0M
$1.2B
Total Assets
INDV
INDV
KMT
KMT
Q1 26
$2.7B
Q4 25
$1.2B
$2.6B
Q3 25
$1.4B
$2.5B
Q2 25
$1.5B
$2.5B
Q1 25
$1.4B
$2.5B
Q4 24
$2.4B
Q3 24
$2.5B
Q2 24
$2.5B
Debt / Equity
INDV
INDV
KMT
KMT
Q1 26
Q4 25
0.45×
Q3 25
0.46×
Q2 25
0.46×
Q1 25
0.48×
Q4 24
0.49×
Q3 24
0.47×
Q2 24
0.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INDV
INDV
KMT
KMT
Operating Cash FlowLast quarter
$-221.0M
Free Cash FlowOCF − Capex
$-245.0M
FCF MarginFCF / Revenue
-68.6%
Capex IntensityCapex / Revenue
6.7%
Cash ConversionOCF / Net Profit
-2.15×
TTM Free Cash FlowTrailing 4 quarters
$-93.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INDV
INDV
KMT
KMT
Q1 26
Q4 25
$-221.0M
$55.1M
Q3 25
$-39.0M
$17.5M
Q2 25
$158.0M
$78.6M
Q1 25
$75.0M
$28.8M
Q4 24
$55.2M
Q3 24
$2.0M
$45.7M
Q2 24
$88.0M
$113.6M
Free Cash Flow
INDV
INDV
KMT
KMT
Q1 26
Q4 25
$-245.0M
$42.4M
Q3 25
$-59.0M
$-5.5M
Q2 25
$141.0M
$57.1M
Q1 25
$70.0M
$5.3M
Q4 24
$35.9M
Q3 24
$-5.0M
$21.0M
Q2 24
$84.0M
$90.3M
FCF Margin
INDV
INDV
KMT
KMT
Q1 26
Q4 25
-68.6%
8.0%
Q3 25
-18.8%
-1.1%
Q2 25
46.7%
11.1%
Q1 25
26.3%
1.1%
Q4 24
7.5%
Q3 24
-1.6%
4.4%
Q2 24
28.1%
16.6%
Capex Intensity
INDV
INDV
KMT
KMT
Q1 26
Q4 25
6.7%
2.4%
Q3 25
6.4%
4.6%
Q2 25
5.6%
4.2%
Q1 25
1.9%
4.8%
Q4 24
4.0%
Q3 24
2.3%
5.1%
Q2 24
1.3%
4.3%
Cash Conversion
INDV
INDV
KMT
KMT
Q1 26
Q4 25
-2.15×
1.63×
Q3 25
-0.93×
0.75×
Q2 25
8.78×
3.64×
Q1 25
1.60×
0.92×
Q4 24
3.08×
Q3 24
0.09×
2.07×
Q2 24
3.06×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

INDV
INDV

Sublocade$233.0M65%
Sublingual And Other$69.0M19%
Other$49.0M14%
Perseris$6.0M2%

KMT
KMT

Americas$298.3M50%
EMEA$174.0M29%
Asia Pacific$120.3M20%

Related Comparisons